Palvella Therapeutics (NASDAQ:PVLA) Earns Buy Rating from HC Wainwright

Palvella Therapeutics (NASDAQ:PVLA)‘s stock had its “buy” rating reiterated by HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $38.00 price target on the stock. HC Wainwright’s target price indicates a potential upside of 35.76% from the stock’s current price.

Other analysts have also issued research reports about the stock. Cantor Fitzgerald assumed coverage on shares of Palvella Therapeutics in a research note on Wednesday, December 18th. They set an “overweight” rating for the company. TD Cowen assumed coverage on shares of Palvella Therapeutics in a research report on Wednesday, February 5th. They set a “buy” rating and a $44.00 target price for the company. Stifel Nicolaus assumed coverage on shares of Palvella Therapeutics in a report on Wednesday, March 26th. They issued a “buy” rating and a $45.00 target price on the stock. Jones Trading initiated coverage on Palvella Therapeutics in a research note on Tuesday, March 25th. They set a “buy” rating and a $45.00 price target for the company. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $39.00 price objective on shares of Palvella Therapeutics in a research note on Wednesday, February 26th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $43.50.

Palvella Therapeutics Stock Performance

NASDAQ PVLA opened at $27.99 on Tuesday. Palvella Therapeutics has a 52 week low of $6.20 and a 52 week high of $29.27. The firm’s 50 day moving average price is $20.54. The company has a market capitalization of $314.08 million, a P/E ratio of -2.31 and a beta of 0.54.

Institutional Trading of Palvella Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Suvretta Capital Management LLC bought a new position in Palvella Therapeutics in the 4th quarter valued at $8,574,000. BVF Inc. IL purchased a new position in shares of Palvella Therapeutics in the 4th quarter worth about $8,359,000. Samsara BioCapital LLC purchased a new position in shares of Palvella Therapeutics in the 4th quarter worth about $8,154,000. Frazier Life Sciences Management L.P. bought a new position in Palvella Therapeutics during the fourth quarter valued at about $7,847,000. Finally, Adams Street Partners LLC purchased a new stake in Palvella Therapeutics during the fourth quarter worth about $4,916,000. 40.11% of the stock is owned by hedge funds and other institutional investors.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.